カテゴリー： Market Monitor Global, 世界, 医療/バイオ

去勢抵抗性前立腺がん治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Castration-resistant Prostate Cancer Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2168）

◆商品コード：MMG23FB2168
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：60
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の去勢抵抗性前立腺がん治療薬市場規模と予測を収録しています。・世界の去勢抵抗性前立腺がん治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の去勢抵抗性前立腺がん治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の去勢抵抗性前立腺がん治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「経口式」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

去勢抵抗性前立腺がん治療薬のグローバル主要企業は、Pfizer、Astellas、Janssen、AstraZeneca、Bayer、Hengrui、CTTQ、Sanofi、Hansoh、Clovis Oncology、Zhendong Pharmaceutical、Merckなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、去勢抵抗性前立腺がん治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の去勢抵抗性前立腺がん治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の去勢抵抗性前立腺がん治療薬市場：タイプ別市場シェア、2022年
・経口式、静脈注射式、その他

世界の去勢抵抗性前立腺がん治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の去勢抵抗性前立腺がん治療薬市場：用途別市場シェア、2022年
・病院、専門クリニック、その他

世界の去勢抵抗性前立腺がん治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の去勢抵抗性前立腺がん治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における去勢抵抗性前立腺がん治療薬のグローバル売上、2018年-2023年
・主要企業における去勢抵抗性前立腺がん治療薬のグローバル売上シェア、2022年
・主要企業における去勢抵抗性前立腺がん治療薬のグローバル販売量、2018年-2023年
・主要企業における去勢抵抗性前立腺がん治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、Astellas、Janssen、AstraZeneca、Bayer、Hengrui、CTTQ、Sanofi、Hansoh、Clovis Oncology、Zhendong Pharmaceutical、Merck

*************************************************************

・調査・分析レポートの概要
去勢抵抗性前立腺がん治療薬市場の定義
市場セグメント
世界の去勢抵抗性前立腺がん治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の去勢抵抗性前立腺がん治療薬市場規模
世界の去勢抵抗性前立腺がん治療薬市場規模：2022年 VS 2029年
世界の去勢抵抗性前立腺がん治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの去勢抵抗性前立腺がん治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の去勢抵抗性前立腺がん治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：経口式、静脈注射式、その他
去勢抵抗性前立腺がん治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門クリニック、その他
去勢抵抗性前立腺がん治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別去勢抵抗性前立腺がん治療薬市場規模 2022年と2029年
地域別去勢抵抗性前立腺がん治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、Astellas、Janssen、AstraZeneca、Bayer、Hengrui、CTTQ、Sanofi、Hansoh、Clovis Oncology、Zhendong Pharmaceutical、Merck
...

This report aims to provide a comprehensive presentation of the global market for Castration-resistant Prostate Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-resistant Prostate Cancer Drugs. This report contains market size and forecasts of Castration-resistant Prostate Cancer Drugs in global, including the following market information:
Global Castration-resistant Prostate Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Castration-resistant Prostate Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Castration-resistant Prostate Cancer Drugs include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi and Hansoh, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Castration-resistant Prostate Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Castration-resistant Prostate Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Oral
Intravenous Injection
Others
Global Castration-resistant Prostate Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialty Clinic
Others
Global Castration-resistant Prostate Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castration-resistant Prostate Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Castration-resistant Prostate Cancer Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Astellas
Janssen
AstraZeneca
Bayer
Hengrui
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Castration-resistant Prostate Cancer Drugs, market overview.
Chapter 2: Global Castration-resistant Prostate Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Castration-resistant Prostate Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Castration-resistant Prostate Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Castration-resistant Prostate Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration-resistant Prostate Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Castration-resistant Prostate Cancer Drugs Overall Market Size
2.1 Global Castration-resistant Prostate Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Castration-resistant Prostate Cancer Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Castration-resistant Prostate Cancer Drugs Players in Global Market
3.2 Top Global Castration-resistant Prostate Cancer Drugs Companies Ranked by Revenue
3.3 Global Castration-resistant Prostate Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Castration-resistant Prostate Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Castration-resistant Prostate Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration-resistant Prostate Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Castration-resistant Prostate Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration-resistant Prostate Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Castration-resistant Prostate Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Oral
4.1.3 Intravenous Injection
4.1.4 Others
4.2 By Type – Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
4.2.1 By Type – Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
4.2.2 By Type – Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
4.2.3 By Type – Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Castration-resistant Prostate Cancer Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialty Clinic
5.1.4 Others
5.2 By Application – Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
5.2.1 By Application – Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
5.2.2 By Application – Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
5.2.3 By Application – Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Castration-resistant Prostate Cancer Drugs Market Size, 2022 & 2029
6.2 By Region – Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
6.2.1 By Region – Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
6.2.2 By Region – Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
6.2.3 By Region – Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.3.2 US Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.3.3 Canada Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.3.4 Mexico Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.4.2 Germany Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.3 France Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.4 U.K. Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.5 Italy Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.6 Russia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.8 Benelux Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.5.2 China Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.3 Japan Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.4 South Korea Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.6 India Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.6.2 Brazil Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.6.3 Argentina Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.7.2 Turkey Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.3 Israel Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.5 UAE Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
7 Castration-resistant Prostate Cancer Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.1.4 Pfizer Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Astellas
7.2.1 Astellas Company Summary
7.2.2 Astellas Business Overview
7.2.3 Astellas Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.2.4 Astellas Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 Astellas Key News & Latest Developments
7.3 Janssen
7.3.1 Janssen Company Summary
7.3.2 Janssen Business Overview
7.3.3 Janssen Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.3.4 Janssen Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Janssen Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.4.4 AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Bayer
7.5.1 Bayer Company Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.5.4 Bayer Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 Bayer Key News & Latest Developments
7.6 Hengrui
7.6.1 Hengrui Company Summary
7.6.2 Hengrui Business Overview
7.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.6.4 Hengrui Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.6.5 Hengrui Key News & Latest Developments
7.7 CTTQ
7.7.1 CTTQ Company Summary
7.7.2 CTTQ Business Overview
7.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.7.4 CTTQ Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.7.5 CTTQ Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.8.4 Sanofi Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.8.5 Sanofi Key News & Latest Developments
7.9 Hansoh
7.9.1 Hansoh Company Summary
7.9.2 Hansoh Business Overview
7.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.9.4 Hansoh Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.9.5 Hansoh Key News & Latest Developments
7.10 Clovis Oncology
7.10.1 Clovis Oncology Company Summary
7.10.2 Clovis Oncology Business Overview
7.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.10.4 Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.10.5 Clovis Oncology Key News & Latest Developments
7.11 Zhendong Pharmaceutical
7.11.1 Zhendong Pharmaceutical Company Summary
7.11.2 Zhendong Pharmaceutical Business Overview
7.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.11.4 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.11.5 Zhendong Pharmaceutical Key News & Latest Developments
7.12 Merck
7.12.1 Merck Company Summary
7.12.2 Merck Business Overview
7.12.3 Merck Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.12.4 Merck Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.12.5 Merck Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 去勢抵抗性前立腺がん治療薬の世界市場見通し2023年-2029年(Castration-resistant Prostate Cancer Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

去勢抵抗性前立腺がん治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp